<DOC>
	<DOCNO>NCT02088112</DOCNO>
	<brief_summary>This Phase I , Open-Label , Multicentre Study ass safety , tolerability , pharmacokinetics preliminary anti-tumour activity gefitinib combination MEDI4736 ( anti PD-L1 ) Subjects Non-small cell lung cancer ( NSCLC ) . The study consist two phase : Escalation phase expansion phase conduct locally advanced metastatic NSCLC subject</brief_summary>
	<brief_title>MEDI4736 ( Anti PD-L1 ) Combined With Gefitinib Subjects With Non-Small Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description>In Escalation phase : MEDI4736 gefitinib NSCLC subject In Expansion phase : Subjects EGFR mutation positive locally advanced metastatic NSCLC enrol expansion arm . Initiation expansion arm recommend dose MEDI4736 combination gefitinib base adequate safety tolerability profile combination escalation phase .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<criteria>Key 1 . Provision sign date , write informed consent 2 . Male female age 18 year old . 3 . Subjects must . In escalation phase , locally advanced metastatic NSCLC subject either fail respond relapse follow line standard treatment , unable tolerate , eligible standard treatment b . In expansion phase , histologically cytologically confirm locally advanced metastatic NSCLC EGFR mutation positive , na√Øve EGFR TKI therapy , sensitive EGFR TKIs therapy 4. a.For Escalation Phase : At least one lesion ( measurable and/or nonmeasurable ) b.For Expansion Phase : At least one measurable lesion . 5 . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . For Japan Escalation global escalation I/E criterion except patient must EGFR mutation positive Key 1 . Any concurrent chemotherapy , immunotherapy , biologic , hormonal therapy cancer treatment . 2 . Any investigational agent , chemotherapy , immunotherapy , biologic , hormonal within 28 day first dose study treatment 3 . Inadequate bone marrow reserve organ function</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>130 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>NSCLC</keyword>
</DOC>